Table 2 Study population characteristics
First author (Ref. No.) | Population | BL RAAS blockade | Tx age | Ct age | Tx gender (F:M or % male) | Ct gender (F:M or % male) | Tx SUA baseline (mg/dL) | Ct SUA baseline (mg/dL) |
|---|---|---|---|---|---|---|---|---|
Katholi [51] | sCr 1.4-2.0 mg/dl and rec contrast | Excluded | 60 ± 4 (NMg), 61 ± 3 (LoMg) | 59 ± 5 (NMg), 63 ± 4 (LoMg) | Not reported | Not reported | Not reported | Not reported |
Perez-Ruiz [56] | Chronic Gout with CrCl 20-80 | Not reported | 60.9 ± 12.8 | 67.3 ± 9.59 | Not reported | Not reported | 9.35 ± 1.96 | 8.96 ± 1.84 |
Kamper [50] | HTN CsA Renal Tr | Minority | M median age 47, W median age 47 | N/A | 10:16 | N/A | 7.90 (median), 4.87-11.60 (range) | N/A |
Schmidt [53] | HTN CsA Renal Tr | Not reported | 58 ± 12 | N/A | 1:12 | N/A | 7.8 ± 2.2 | 7.8 ± 1.8 |
Doehner [35] | LV dysfxn (EF < 40%), hyperUA >400 umol/L | Not reported | 68 ± 2 | 69 ± 3 | 100% male | 100% male | 8.99 ± 0.37 | 9.88 ± 0.62 |
Chanard [54] | HTN CsA Renal Tr | Not reported | 45.2 ± 9.9 | 48.2 ± 11.5 | 7:17 | 8:16 | 8.11 ± 1.66 | 7.56 ± 1.65 |
Siu [48] | sCr 120-400 umol/L | Majority | 47.7 ± 12.9 | 48.8 ± 16.8 | 9:4 | 13:15 | 9.75 ± 1.18 | 9.92 ± 1.68 |
Liu [36] | CKD (120-400 umol/L) and hyperUA | Not reported | 45.6 ± 12.5 | 46.5 ± 13. 8 | 8:16 | 10:13 | 9.73 ± 0.20 | 9.92 ± 0.26 |
Sarris [34] | hyperUA > 7 mg/dL, mild-mod CKD, sCr >1.5, <3.0 mg/dL | Not reported | 49.2 ± 17.3 | 50.4 ± 15.8 | 8:10 | 11:7 | 8.88 ± 1.26 | 9.16 ± 1.46 |
Lei [40] | CKD with hyperUA | Not reported | 48.6 ± 10.2 | 49.5 ± 9.8 | 9:20 | 9:19 | 8.84 ± 1.45 | 8.70 ± 1.41 |
Malaguarnera [55] | hyperUA, 65-85 yrs, sCr 2.5 mg/dl | Approximately half | 75.6 ± 8.4 | 76.4 ± 8.1 | 15:5 | 12:6 | 10.9 ± 2.9 | 10.3 ± 3.1 |
Nouri-Majalan [52] | Pts undergoing CABG and eGFR < 60 | Not reported | 65 ± 9.5 | 61 ± 7.90 | 13:17 | 16:14 | Not reported | Not reported |
Deng [37] | CKD | Not reported | 60.0 ± 11.1 | 58.8 ± 9.4 | 15:14 | 14:18 | 8.59 ± 1.01 | 8.93 ± 0.96 |
Goicoechea [44] | CKD Stage 3-5 | Majority | 72.1 ± 7.9 | 71.4 ± 9.5 | Not reported | Not reported | 7.8 ± 2.1 | 7.3 ± 1.6 |
Momeni [46] | T2DM Nephropathy | Majority | 56.3 ± 10.6 | 59.1 ± 10.6 | 11:9 | 11:9 | 5.96 ± 1.21 | 6.5 ± 2.2 |
Shen [38] | CKD with hyperUA | Not reported | 47.1 ± 11.8 | 47.6 ± 12.4 | 8:18 | 9:17 | 9.01 ± 1.38 | 8.89 ± 1.50 |
Kao [45] | LVH and CKD Stage 3 | Majority | 70.6 ± 6.9 | 73.7 ± 5.3 | 59% male | 46% male | 7.39 ± 1.5 | 7.06 ± 1.3 |
Tan [39] | T2DM nephropathy eGFR, 30-60 ml/min/1.73 m2 | Majority | 59.3 ± 9.2 | 58.6 ± 8.3 | 35:37 | 33:35 | 8.93 ± 0.96 | 8.60 ± 1.01 |
Shi [47] | IgA nephropathy and hyperUA | Excluded | 39.7 ± 10.0 | 40.1 ± 10.8 | 8:13 | 10:9 | 7.9 ± 1.1 | 7.8 ± 1.1 |